Northwire Canada EditionMonday, July 13, 2026
Sign inSubscribe
Northwire
⌕
GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0% GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0%
Production / Operations

PharmAla Biotech Australia Contracts with UK-based CDMO for Manufacture of ALA-002 Drug Substance

By The Northwire Desk — AI Analysis Dec 15, 2025 · 08:30 MDMA · 0.11 Pharmala Biotech Holdings Inc.
MDMA · Price

Executive Summary

  • PharmAla Biotech Australia has secured a contract with a UK‑based CDMO to manufacture the drug substance for its novel MDMA formulation ALA‑002.
  • The partnership is a key prerequisite for launching the Phase 2a/2b clinical trial of ALA‑002 in 2026 targeting Social Anxiety Disorder.
  • The company completed one of two scheduled shipments of LaNeo™ MDMA to Mount Sinai’s Parsons Research Center for use in ongoing psychedelic‑healing research.

Key Details

  • Contract with UK CDMO:
  • Sub‑contract awarded to an undisclosed United Kingdom contract development and manufacturing organization (CDMO) for process development and bulk manufacture of ALA‑002 drug substance.

  • Execution follows a global RFP conducted by PharmAla Biotech Australia.

  • ALA‑002 Development Milestone:

  • First new active pharmaceutical ingredient (API) development since 2022.

  • Patent‑protected, non‑racemic MDMA formulation intended for Phase 2a/2b clinical trials in 2026.

  • Clinical Trial Timeline:

  • Planned initiation of Phase 2a/2b trial to evaluate ALA‑002 for Social Anxiety Disorder in 2026, contingent on successful manufacturing scale‑up.

  • Shipment to Mount Sinai:

  • Completed one of two contracted shipments of LaNeo™ MDMA to the Parsons Research Center at Mt. Sinai Hospital for clinical research purposes (originally announced Oct 21, 2024).

  • Forward‑Looking Statements:

  • The release contains forward‑looking information regarding manufacturing timelines, trial initiation, and regulatory expectations.

Notable Quotes

“PharmAla Australia worked diligently, executing a global RFP search to find our ideal partner for process development and manufacturing of the ALA‑002 drug product components,” – Nick Kadysh, Founding CEO, PharmAla Biotech.

“This is an important and necessary step to us executing our ALA‑002 Phase 2 clinical trial in 2026, and the first time since 2022 that PharmAla will be developing a wholly new Active Pharmaceutical Ingredient for human use.” – Nick Kadysh, Founding CEO, PharmAla Biotech.

Read the original news release →

More from Pharmala Biotech Holdings Inc.

May 20, 2026 · 08:15

PharmAla’s ALA-002 draws a nine-figure pact with Nasdaq-listed Jupiter, signalling Big Pharma-style validation for next-gen MDMA in a transformed U.S. regulatory landscape.

Other May 20, 2026 · 07:38

PharmAla’s $100M-Plus ALA-002 Licensing Pact with Nasdaq’s Jupiter Validates Next-Gen MDMA, Fueling a Pivotal Re-Rating

M&A / Property May 13, 2026 · 08:30

PharmAla Advances APA-01 SPV Deal; Royalty Stream Contingent on Funding

M&A / Property Apr 27, 2026 · 08:00

PharmAla Biotech Monetizes APA-01 IP via SPV Amidst Psychedelic Regulatory Tailwinds

Other Apr 21, 2026 · 16:05

PharmAla Biotech Gains on Regulatory Tailwinds as Earnings Confirm Growth Amidst Management Shake-Up

Earnings Apr 20, 2026 · 08:15

CSE: MDMA

Production / Operations